Myasthenia Gravis

Disclaimer: This information is intended for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional, taking into account the individual patient's circumstances, clinical judgment, and the latest evidence.

Overview

Definition

Myasthenia Gravis (MG) is a chronic, autoimmune neuromuscular disease characterized by fluctuating weakness and fatigability of voluntary muscles. It results from an antibody-mediated attack on proteins at the neuromuscular junction (NMJ), most commonly the acetylcholine receptor (AChR), leading to impaired synaptic transmission between nerve and muscle.

Epidemiology

• Incidence: Approximately 1-2 per 100,000 person-years.
• Prevalence: Ranges from 15 to 20 per 100,000 population, but likely higher due to improved diagnosis.
• Age: Bimodal distribution.
  • First peak: Females in their 20s and 30s.
  • Second peak: Males in their 60s and 70s.
• Sex: Overall female predominance (ratio 3:2), but males are more commonly affected in late-onset MG.
• Ethnicity: Occurs worldwide across all ethnic groups.

Classification

MG is classified based on clinical features, autoantibody status, age of onset, and thymic pathology.

• According to Muscle Involvement:
  • Ocular Myasthenia Gravis (OMG): Weakness limited to the eye muscles (ptosis, diplopia) for at least one year. Approximately 50% of generalized MG cases begin as OMG.
  • Generalized Myasthenia Gravis (G-MG): Weakness affecting ocular muscles and other non-ocular muscles (bulbar, limb, axial, respiratory).
• According to Autoantibody Status:
  • AChR Antibody-Positive MG (AChR-MG): Most common form (85-90% of G-MG, 50-70% of OMG).
  • Muscle-Specific Kinase Antibody-Positive MG (MuSK-MG): Accounts for 4-10% of G-MG, often associated with more severe bulbar and respiratory weakness, and often no thymic abnormalities. Patients with MuSK-MG are typically AChR-antibody negative.
  • Low-Density Lipoprotein Receptor-Related Protein 4 Antibody-Positive MG (LRP4-MG): Accounts for a small percentage (approx. 2%) of AChR- and MuSK-antibody negative MG.
  • Seronegative Myasthenia Gravis (SNMG): Approximately 5-10% of patients have clinical MG but are negative for all known autoantibodies. Other autoantibodies (e.g., agrin, titin, ryanodine receptor) may be present in a subset.
• According to Age of Onset:
  • Early-Onset MG (EOMG): Onset typically before age 50, often associated with thymic hyperplasia.
  • Late-Onset MG (LOMG): Onset typically after age 50, often associated with thymic atrophy or thymoma.
  • Juvenile Myasthenia Gravis (JMG): Onset before age 18.
• Other Forms:
  • Myasthenia Gravis with Thymoma: Approximately 10-15% of MG patients have a thymoma.
  • Neonatal Myasthenia Gravis: Transient weakness in infants born to mothers with MG due to transplacental transfer of antibodies. Typically resolves within weeks to months.

Pathophysiology

Mechanism

MG is an autoimmune disease where the body's immune system erroneously produces antibodies that target proteins at the NMJ, disrupting the normal communication between motor nerves and skeletal muscles.

1. Acetylcholine Receptor (AChR) Antibodies:

   • The most common target (85-90% of G-MG).
   • Antibodies bind to postsynaptic AChRs, leading to:
     • Accelerated degradation: Cross-linking and internalization of AChRs, reducing their number on the muscle membrane.
     • Blockade: Direct binding of antibodies to the AChR, preventing acetylcholine (ACh) from binding.
     • Complement-mediated destruction: Activation of the complement cascade, leading to destruction of the postsynaptic membrane and reduction in the number of functional AChRs.
   • This results in a reduced amplitude of end-plate potentials (EPPs) and, consequently, a failure to reach the threshold for muscle fiber depolarization, leading to muscle weakness.
   • Weakness worsens with repeated muscle activity because ACh release decreases with repeated stimulation, further exacerbating the impaired transmission.

2. Muscle-Specific Kinase (MuSK) Antibodies:

   • MuSK is a receptor tyrosine kinase located on the postsynaptic membrane, crucial for the formation and maintenance of the NMJ by clustering AChRs.
   • Antibodies against MuSK impair AChR clustering, leading to reduced AChR numbers and abnormal NMJ architecture.
   • Complement activation is generally not a prominent feature in MuSK-MG.

3. LRP4 Antibodies:

   • LRP4 is a receptor that acts as a co-receptor for agrin (a nerve-derived proteoglycan) in activating MuSK, thereby promoting AChR clustering.
   • LRP4 antibodies interfere with agrin-LRP4-MuSK signaling.

4. Role of the Thymus:

   • The thymus gland is believed to play a central role in the pathogenesis of AChR-MG.
   • In about 65-70% of EOMG patients, the thymus shows lymphoid follicular hyperplasia, containing germinal centers with B cells, T cells, and antigen-presenting cells that produce AChR antibodies.
   • In 10-15% of MG patients (more common in LOMG), a thymoma (a tumor of thymic epithelial cells) is present. Thymomas contain myoid cells that express AChRs, potentially triggering an autoimmune response.

Risk Factors

• Genetic Predisposition: Certain HLA alleles (e.g., HLA-DR3, HLA-B8) are associated with increased risk, particularly for EOMG.
• Thymoma: Presence of a thymoma is a significant risk factor for developing MG.
• Other Autoimmune Diseases: MG often coexists with other autoimmune conditions (e.g., thyroid disease, rheumatoid arthritis, systemic lupus erythematosus).
• Certain Medications:
  • Known to induce or exacerbate MG: D-penicillamine (can induce reversible MG), quinidine, procainamide, beta-blockers, aminoglycoside antibiotics (e.g., gentamicin), fluoroquinolones, macrolide antibiotics (e.g., azithromycin, clarithromycin), magnesium, botulinum toxin, immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab).
  • Use with caution: Neuromuscular blocking agents (depolarizing and non-depolarizing), opioids, sedatives.
• Infections: Viral or bacterial infections can trigger or exacerbate MG symptoms.
• Stress: Physical or emotional stress can worsen symptoms.
• Surgery: Can exacerbate symptoms, especially if respiratory muscles are involved.
• Pregnancy: Hormonal changes during pregnancy can alter disease course, sometimes for the worse.

Protective Factors

There are no specific known "protective factors" that prevent the development of autoimmune myasthenia gravis. However, strategies that contribute to better management and reduced disease burden include: * Early Diagnosis and Treatment: Timely and effective management can significantly improve prognosis and prevent disease progression and crises. * Avoidance of Exacerbating Factors: Educating patients to avoid medications known to worsen MG and to manage infections or stress can prevent exacerbations. * Healthy Lifestyle: General health practices like regular sleep, balanced diet, and moderate exercise (within limits of fatigability) can support overall well-being.

Clinical Presentation

Signs and Symptoms

MG is characterized by fluctuating muscle weakness that worsens with sustained activity and improves with rest. Symptoms are typically worse later in the day.

Cardinal Features

• Ocular Weakness:
  • Ptosis: Drooping of one or both eyelids, often asymmetric. It can be variable throughout the day or with fatigue.
  • Diplopia: Double vision, often horizontal or vertical, due to weakness of extraocular muscles.
• Bulbar Weakness:
  • Dysphagia: Difficulty swallowing, leading to choking, nasal regurgitation, or hoarseness.
  • Dysarthria: Slurred speech, often with a nasal or "dysphonia" quality, worsening with prolonged speaking.
  • Mastication weakness: Difficulty chewing, especially with tough foods, leading to jaw fatigue.
  • Facial weakness: Impaired facial expressions (e.g., "myasthenic sneer" when attempting to smile, inability to close eyes tightly).
• Limb Weakness:
  • Proximal muscles are more often affected than distal, especially in the neck and shoulders, leading to difficulty lifting arms above the head, combing hair, or rising from a chair.
  • Foot drop or wrist drop can occur but are less common initial features.
• Respiratory Weakness:
  • Weakness of diaphragm and intercostal muscles, leading to shortness of breath, exertional dyspnea, or orthopnea. This is a critical symptom, potentially leading to myasthenic crisis.
• Neck Weakness:
  • "Head drop" due to weakness of neck extensors, or difficulty holding the head up.

Early Signs

• In >50% of cases, symptoms begin with ocular involvement (ptosis and/or diplopia).
• About 15% begin with bulbar symptoms.
• Less commonly, initial symptoms are limb weakness.

Advanced Signs

• Generalized Weakness: Affecting multiple muscle groups, including ocular, bulbar, limb, and respiratory muscles.
• Myasthenic Crisis: Severe, life-threatening respiratory muscle weakness requiring mechanical ventilation. Often precipitated by infection, surgery, or certain medications.
• Bulbar Crisis: Severe dysphagia and dysarthria with aspiration risk, often preceding or co-occurring with respiratory crisis.

Atypical Presentations

• Isolated Limb Weakness: Can occur, mimicking other neuromuscular disorders.
• MG "Mimics": Symptoms may be mistaken for stroke, brainstem lesions, or other myopathies.
• Fluctuating Nature: The hallmark fluctuation and fatigability may be subtle or missed, especially early in the disease course.

Physical Examination

Inspection

• Ptosis: Observe for unilateral or bilateral eyelid drooping, variability, and worsening with sustained upgaze.
• Facial Expression: Look for symmetric or asymmetric facial weakness, "myasthenic sneer," or poor eye closure.
• Head Position: Observe for "head drop" or difficulty maintaining head posture.
• Swallowing: Observe for signs of dysphagia (e.g., coughing after sips of water).

Palpation

• Generally not useful in the diagnosis of MG. Muscles are not tender or atrophied early in the disease.

Special Tests

• Fatigability Testing:
  • Sustained Upgaze Test: Patient gazes upwards for 30-60 seconds. Observe for worsening ptosis or onset of diplopia.
  • Count to 50/100: Patient counts aloud. Observe for progressive dysarthria or hypophonia.
  • Repetitive Arm Abductions: Patient rapidly abducts and adducts arms. Observe for rapidly developing shoulder weakness.
  • Repetitive Blinking: Patient blinks repeatedly. Observe for worsening ptosis.
• Ice Pack Test:
  • Apply an ice pack to a ptotic eyelid for 2-5 minutes. The cold improves neuromuscular transmission, leading to temporary improvement in ptosis (a positive test is significant eyelid elevation of ≥2 mm). Highly specific for MG, especially ocular MG.
• Sleep Test:
  • Similar principle to the ice pack test. A 30-minute nap can temporarily improve symptoms, especially ocular.
• Forced Vital Capacity (FVC):
  • Crucial for assessing respiratory muscle strength. A bedside measurement that should be performed regularly, especially in patients with bulbar or generalized weakness. A decreasing FVC (e.g., <20 mL/kg or <1.5 L) indicates impending respiratory failure and myasthenic crisis.
• Negative Inspiratory Force (NIF) / Maximal Inspiratory Pressure (MIP):
  • Measures inspiratory muscle strength. Can also indicate respiratory compromise.

Diagnostic Approach

History Taking

Key Questions

• Nature of Weakness:
  • Is weakness fluctuating? Does it worsen with activity and improve with rest?
  • Is there a diurnal variation (worse later in the day)?
  • Which muscles are affected (eyes, eyelids, face, jaw, throat, neck, limbs, breathing)?
• Onset and Progression: When did symptoms start? How rapidly did they progress?
• Specific Symptoms:
  • Ocular: Diplopia (horizontal/vertical, constant/intermittent, worse with fatigue), ptosis (unilateral/bilateral, variable throughout the day, worse when tired).
  • Bulbar: Dysphagia (choking, nasal regurgitation), dysarthria (slurred, nasal voice), difficulty chewing, fatigue with prolonged speaking.
  • Limb: Difficulty lifting arms, climbing stairs, standing from a chair, weakness after exertion.
  • Respiratory: Shortness of breath, orthopnea, waking up gasping for air.
• Precipitating Factors: Infections, stress, hot weather, surgery, specific medications (ask about all new medications, including over-the-counter and supplements).
• Associated Conditions: History of thymoma, thyroid disease, or other autoimmune disorders.
• Family History: Any family history of MG or other autoimmune diseases.

Red Flags

• Rapidly Progressive Weakness: Especially involving bulbar and respiratory muscles, indicating impending or actual myasthenic crisis.
• New or Worsening Dysphagia: Significant risk of aspiration.
• Dyspnea or Shortness of Breath: Even mild respiratory distress warrants immediate evaluation of respiratory mechanics (FVC, NIF).
• Drooling or Secretion Management Issues: Suggests severe bulbar weakness.

Laboratory Tests

First-Line

• Acetylcholine Receptor Binding Antibodies (AChR-Ab):
  • Present in 85-90% of G-MG and 50-70% of OMG.
  • Highly specific (~99%). A positive result is usually diagnostic of MG.
  • Value: A titer above the laboratory's reference range (e.g., >0.2 nmol/L) is considered positive. The titer does not correlate well with disease severity or response to treatment.

Confirmatory

• Muscle-Specific Kinase Antibodies (MuSK-Ab):
  • Should be tested in AChR-Ab negative G-MG patients, especially those with prominent bulbar or respiratory weakness.
  • Present in 4-10% of overall MG patients.
• Low-Density Lipoprotein Receptor-Related Protein 4 Antibodies (LRP4-Ab):
  • Consider testing in patients negative for both AChR-Ab and MuSK-Ab.
  • Present in a small percentage (approx. 2%) of "seronegative" MG.
• Thyroid Function Tests (TSH, free T4):
  • To screen for co-existing autoimmune thyroid disease (Grave's disease or Hashimoto's thyroiditis), which occurs in 5-10% of MG patients.
• Electrophysiological Studies:
  • Repetitive Nerve Stimulation (RNS):
    • Performed by applying repetitive electrical stimuli (2-3 Hz) to a nerve while recording muscle compound muscle action potentials (CMAPs).
    • Positive Finding: A decrement of >10% in the amplitude of the CMAP from the first to the fifth potential in at least one muscle.
    • Sensitivity: Variable (60-75% in G-MG, lower in OMG). More sensitive in proximal and facial muscles.
  • Single-Fiber Electromyography (SFEMG):
    • Considered the most sensitive electrophysiological test for MG (>95%).
    • Measures the variability in the time interval between action potentials of two muscle fibers innervated by the same motor neuron (jitter) and the occurrence of impulse blocking (failure of one fiber to fire).
    • Positive Finding: Increased jitter and/or blocking in at least two muscles.
    • Can detect NMJ dysfunction even in clinically unaffected muscles.

Imaging

Recommended

• Computed Tomography (CT) Scan of the Chest with Contrast:
  • Purpose: To evaluate the thymus gland for thymoma or thymic hyperplasia.
  • Recommendation: All patients diagnosed with MG should undergo a CT scan of the chest.
  • Findings: Thymoma (10-15%), thymic hyperplasia (60-70% in EOMG), or normal/atrophic thymus.

Advanced

• Magnetic Resonance Imaging (MRI) of the Chest:
  • May be considered if CT findings are equivocal or if better soft tissue differentiation is needed, especially in younger patients to avoid radiation exposure.
• Cerebral/Orbital MRI:
  • Only if central neurological causes for ocular symptoms (e.g., brainstem stroke, tumor) or other neurological conditions are suspected, as MG can be mistaken for other disorders. Not a primary diagnostic tool for MG itself.

Management

Acute Management

Acute management focuses on stabilizing patients during a myasthenic crisis or severe exacerbation.

Immediate

1. Airway Assessment: Rapid assessment of respiratory distress, bulbar weakness, and ability to clear secretions.
2. Vital Signs: Monitor oxygen saturation, respiratory rate, heart rate, and blood pressure closely.
3. Identify Triggers: Search for precipitating factors such as infection, surgery, new medications (especially contraindicated ones), or emotional stress.

Stabilization

1. Respiratory Support:
   • Non-invasive ventilation (NIV): Consider if respiratory distress is mild-moderate (e.g., FVC >1.5L but declining, or symptoms of dyspnea) and patient is cooperative.
   • Intubation and Mechanical Ventilation: Indicated for impending or actual respiratory failure (e.g., FVC <1.0-1.5 L, significant CO2 retention, inability to clear secretions, progressive hypoxemia, or signs of exhaustion).
2. Pharmacological Therapy (Rapid Immunomodulation):
   • Intravenous Immunoglobulin (IVIG):
     • Mechanism: Broad immunomodulatory effects, including neutralizing pathogenic antibodies, modulating complement, and altering T/B cell function.
     • Dose: 2 g/kg total dose, typically administered over 2-5 days (e.g., 0.4 g/kg/day for 5 days).
     • Onset of Action: Days to a week.
     • Side Effects: Headache, fever, chills, aseptic meningitis, renal dysfunction, thrombotic events.
   • Plasmapheresis (Plasma Exchange, PLEX):
     • Mechanism: Directly removes circulating pathogenic antibodies, complement components, and inflammatory mediators from the plasma.
     • Dose: Typically 5 exchanges of 1-1.5 plasma volumes over 7-10 days.
     • Onset of Action: Rapid, within days.
     • Side Effects: Hypotension, paresthesias (due to citrate), electrolyte disturbances, infection, access complications.
   • Choice between IVIG and PLEX: Both are equally effective for acute crisis. Choice depends on patient tolerance, contraindications (e.g., renal failure for IVIG, unstable hemodynamics for PLEX), and availability.
3. Cholinergic Medications:
   • Pyridostigmine: Usually withheld or significantly reduced during acute crisis, especially if bulbar weakness is severe, to prevent aspiration and avoid cholinergic crisis (which can mimic myasthenic crisis but is rare). Reintroduce cautiously once patient stabilizes.

Emergency

• Myasthenic Crisis: Defined as severe MG exacerbation requiring intubation and mechanical ventilation, or presenting with life-threatening bulbar weakness leading to aspiration/airway obstruction. This is a medical emergency requiring ICU admission.
  • Management: Intubation, mechanical ventilation, IVIG or PLEX, supportive care, and identification/treatment of precipitating factors (e.g., antibiotics for infection).

Chronic Management

Aims to reduce autoimmune attack and improve muscle strength and function.

Pharmacological

1. Anticholinesterase Inhibitors (Symptomatic Treatment):

   • Pyridostigmine (Mestinon):
     • Mechanism: Reversibly inhibits acetylcholinesterase, increasing acetylcholine concentration at the NMJ, thereby improving muscle strength.
     • Dose: Start at 30-60 mg orally every 4-6 hours during waking hours. Can be titrated up to 120 mg every 3-4 hours, typically not exceeding 600 mg/day. A sustained-release form (Mestinon Timespan) is available for nocturnal symptoms, but absorption can be erratic.
     • Side Effects: Cholinergic side effects (diarrhea, abdominal cramps, increased salivation, bradycardia, muscle fasciculations), which can be managed with lower doses or anticholinergics like atropine (rarely needed).
     • Note: Provides symptomatic relief but does not alter the underlying autoimmune process.

2. Immunosuppressants (Disease-Modifying Treatment):

   • Corticosteroids:
     • Prednisone: First-line immunosuppressant for generalized MG.
     • Mechanism: Suppress the immune system, reducing antibody production.
     • Dose: Highly individualized. Common approaches:
       • Slow escalation: Start at low dose (e.g., 15-20 mg/day) and increase by 5-10 mg weekly to 0.5-1 mg/kg/day (up to 60 mg/day). This reduces risk of initial worsening.
       • High dose upfront: 1 mg/kg/day (up to 60-100 mg/day). Faster improvement but higher risk of initial exacerbation.
       • Once significant improvement is achieved, gradually taper to the lowest effective dose, often on an alternate-day regimen.
     • Side Effects: Weight gain, fluid retention, hypertension, hyperglycemia, osteoporosis, cataracts, increased infection risk, mood changes. Prophylaxis for osteoporosis (calcium, vitamin D, bisphosphonates) and regular monitoring are crucial.
   • Steroid-Sparing Immunosuppressants: Added to corticosteroids to allow for steroid reduction or withdrawal, or for patients with inadequate response to steroids.
     • Azathioprine (Imuran):
       • Dose: Start at 50 mg/day, gradually increase over weeks to months to 2-3 mg/kg/day (typically 100-200 mg/day).
       • Onset of Action: Slow (6-12 months).
       • Monitoring: CBC (for leukopenia, macrocytosis), LFTs (for hepatotoxicity). Genotype for TPMT deficiency (thiopurine methyltransferase) to prevent myelosuppression.
     • Mycophenolate Mofetil (CellCept):
       • Dose: 1-1.5 g twice daily.
       • Onset of Action: Slower (3-6 months), but generally faster than azathioprine.
       • Side Effects: Gastrointestinal (nausea, diarrhea), myelosuppression, increased infection risk.
     • Cyclosporine:
       • Dose: 2-5 mg/kg/day in two divided doses. Monitor blood levels.
       • Onset of Action: Faster than azathioprine/mycophenolate (2-4 months).
       • Side Effects: Nephrotoxicity, hypertension, hirsutism, gingival hyperplasia.
     • Tacrolimus:
       • Dose: 0.05-0.1 mg/kg/day in two divided doses. Monitor blood levels.
       • Side Effects: Similar to cyclosporine (nephrotoxicity, hyperglycemia, neurotoxicity).
     • Methotrexate: Less commonly used for MG, but an option for refractory cases.
   • Biologic Therapies (for Refractory MG):
     • Rituximab (Rituxan):
       • Mechanism: Anti-CD20 monoclonal antibody, depletes B cells.
       • Indication: Often considered for refractory AChR-MG, and particularly effective in MuSK-MG.
       • Dose: 375 mg/m² weekly for 4 doses, or 1000 mg IV on Day 1 and Day 15. Dosing varies.
     • Eculizumab (Soliris) / Ravulizumab (Ultomiris):
       • Mechanism: Complement C5 inhibitors, preventing complement-mediated damage at the NMJ.
       • Indication: Approved for generalized AChR-positive MG in patients who remain symptomatic despite conventional therapy.
       • Note: Require meningococcal vaccination before initiation due to increased risk of Neisseria meningitidis infection.
     • Efgartigimod (Vyvgart):
       • Mechanism: FcRn inhibitor, reduces circulating IgG antibodies (including pathogenic autoantibodies) by blocking their recycling.
       • Indication: Approved for generalized AChR-positive MG.
       • Dose: 10 mg/kg IV once weekly for 4 weeks. Subsequent cycles based on clinical response.
     • Zilucoplan (Zilbrysq):
       • Mechanism: Subcutaneous C5 inhibitor.
       • Indication: Approved for generalized AChR-positive MG.
     • Rozanolixizumab (Rystiggo):
       • Mechanism: FcRn inhibitor.
       • Indication: Approved for generalized AChR-positive or MuSK-positive MG.

Non-Pharmacological

• Thymectomy:
  • Indications:
    • All patients with thymoma: Surgical removal is mandatory to prevent local invasion or metastasis, even if MG symptoms are mild. Thymectomy can also improve MG symptoms.
    • Generalized AChR-positive MG without thymoma: Recommended, especially for patients aged <65 years (EOMG), as it can lead to improved clinical outcomes, reduced need for immunosuppression, and even remission. Evidence from MGTX trial supports this.
  • Approach: Minimally invasive techniques (e.g., transcervical, thoracoscopic) are increasingly favored over open sternotomy.
• Lifestyle Modifications:
  • Rest: Pacing activities and taking frequent rests can help manage fatigability.
  • Avoidance of Triggers: Patient education on identifying and avoiding exacerbating factors (e.g., specific medications, extreme temperatures, stress, infections).
  • Diet: No specific diet, but a healthy, balanced diet is important. For dysphagia, soft foods, thick liquids, small frequent meals may be necessary.
• Supportive Care:
  • Physical Therapy/Occupational Therapy: To maintain strength, prevent deconditioning, and adapt daily activities.
  • Speech Therapy: For dysphagia and dysarthria.
  • Eye Care: Prisms for diplopia, artificial tears for dry eyes due to incomplete lid closure, or eyelid crutches for ptosis.
  • Vaccinations: Ensure patients on immunosuppressants receive appropriate vaccinations (e.g., influenza, pneumococcal, COVID-19). Live vaccines are generally contraindicated in immunosuppressed patients.

Monitoring

• Clinical Status: Regular assessment of muscle strength, fatigability, bulbar function, and respiratory status. Use standardized scales (e.g., Myasthenia Gravis-Activities of Daily Living (MG-ADL) scale, Quantitative Myasthenia Gravis (QMG) score).
• Pulmonary Function Tests (PFTs): Routine FVC and NIF measurements, especially during periods of instability or with bulbar involvement.
• Medication Side Effects: Close monitoring for adverse effects of corticosteroids and immunosuppressants (e.g., blood counts, liver/kidney function, bone density, glucose).
• Antibody Titers: While helpful for diagnosis, antibody titers generally do not correlate well with disease severity or guide treatment decisions for long-term monitoring.

Treatment Algorithms

First-Line

1. Symptomatic Relief: Pyridostigmine for all patients. Titrate to effect while monitoring for cholinergic side effects.
2. Disease Modification (if symptoms not controlled by pyridostigmine alone):
   • Corticosteroids (Prednisone): Start with a low dose and gradually increase (or high dose if rapid control needed) until improvement, then taper slowly to lowest effective dose.
   • Thymectomy: For generalized AChR-positive MG patients aged <65 years without thymoma, and all patients with thymoma regardless of age.

Second-Line

1. Steroid-Sparing Immunosuppressants:
   • If unable to taper corticosteroids due to symptom recurrence, or for long-term management to minimize steroid side effects.
   • Azathioprine or Mycophenolate Mofetil are typically preferred due to established efficacy and side effect profiles.
   • Cyclosporine or Tacrolimus are alternatives if others are ineffective or not tolerated.
2. IVIG or PLEX: For acute exacerbations, but not for chronic maintenance.

Refractory Cases

• Patients who remain significantly symptomatic despite optimal dosing of corticosteroids and at least one other conventional immunosuppressant (e.g., azathioprine or mycophenolate).
• Consider Biologic Therapies:
  • Rituximab: Especially effective in MuSK-MG and for some AChR-MG.
  • Eculizumab/Ravulizumab: For generalized AChR-positive MG.
  • Efgartigimod/Zilucoplan/Rozanolixizumab: Newer options for generalized AChR-positive MG (and Rozanolixizumab for MuSK-positive).
• Consider Combination Therapy: Sometimes, a combination of immunosuppressants might be used, but this requires careful risk-benefit assessment due to increased immunosuppression.
• Repeat IVIG/PLEX: For severe exacerbations or as a bridging therapy.

Complications

Common

• Fatigue: Persistent, debilitating fatigue is common, even when muscle strength is relatively controlled.
• Dysphagia and Dysarthria: Leading to communication difficulties, social isolation, and potential aspiration.
• Medication Side Effects: Chronic steroid use (osteoporosis, diabetes, hypertension, cataracts), immunosuppression (infections, gastrointestinal upset, myelosuppression).
• Aspiration Pneumonia: Due to bulbar weakness.

Serious

• Myasthenic Crisis: Life-threatening respiratory failure requiring mechanical ventilation.
• Aspiration and Choking: Severe bulbar weakness leading to airway compromise.
• Cholinergic Crisis: Rarely, due to excessive anticholinesterase medication, leading to profound weakness, respiratory failure, and cholinergic symptoms (salivation, lacrimation, urination, defecation, GI upset, emesis). Clinically, it can resemble myasthenic crisis, requiring careful differentiation. The Tensilon (edrophonium) test can help differentiate (improves weakness in MG crisis, worsens in cholinergic crisis), but is risky in crisis.
• Infections: Increased risk due to immunosuppressive therapy.
• Thymoma-associated complications: Local invasion, rarely metastasis.

Long-term

• Chronic Weakness and Disability: Can significantly impact quality of life and independence.
• Osteoporosis: A major long-term complication of chronic corticosteroid use.
• Cardiomyopathy: Rare, associated with antibodies against titin and ryanodine receptor, particularly in thymoma-associated MG.
• Other Autoimmune Diseases: Increased risk of developing other autoimmune conditions.

Prognosis

Factors

• Age of Onset: EOMG (onset <50 years) generally has a better prognosis, higher rates of remission, and better response to thymectomy. LOMG (onset >50 years) tends to have a more severe course, particularly affecting bulbar and respiratory muscles, and lower remission rates, although response to treatment is often good.
• Antibody Type:
  • AChR-MG: Highly variable course, good response to treatment, including thymectomy.
  • MuSK-MG: Often associated with more severe bulbar and respiratory weakness, less response to anticholinesterase inhibitors, and generally no benefit from thymectomy. Can be more challenging to treat.
  • Seronegative MG: Variable, can range from mild to severe, often good response to immunosuppression.
• Thymoma: Presence of thymoma often indicates a more severe and refractory course, even after thymectomy.
• Initial Severity: More severe initial symptoms (especially bulbar/respiratory) are associated with a greater risk of crisis and worse long-term outcomes.
• Early and Aggressive Treatment: Prompt diagnosis and initiation of appropriate immunosuppressive therapy are crucial for better outcomes.

Survival

• With modern treatment, the prognosis for MG has dramatically improved. Mortality rates have decreased significantly, from as high as 30-40% in the pre-immunosuppressant era to 1-3% currently.
• Most deaths are related to myasthenic crisis (respiratory failure, aspiration pneumonia) or complications of long-term immunosuppression.

Quality of Life

• Many patients achieve good control of symptoms and a near-normal quality of life with appropriate treatment.
• However, even with treatment, some patients experience persistent fluctuating weakness, fatigue, and side effects from medication, which can significantly impact daily activities and emotional well-being.
• Remission (symptom-free with no treatment) or pharmacological remission (symptom-free on minimal treatment) occurs in a significant proportion of patients, particularly those with EOMG who undergo thymectomy.

Prevention

Primary

There are no known primary prevention strategies to prevent the initial occurrence of autoimmune myasthenia gravis, as it is an autoimmune disease.

Secondary

Secondary prevention focuses on early diagnosis and timely intervention to prevent disease progression, severe exacerbations, and complications. * Early Diagnosis: Recognizing early signs and symptoms (e.g., fluctuating ptosis, diplopia) and promptly initiating diagnostic work-up. * Appropriate and Timely Treatment: Prompt initiation of anticholinesterase inhibitors, immunosuppressants, and consideration of thymectomy to control symptoms and modify disease course. * Patient Education: Informing patients about their condition, potential triggers (e.g., contraindicated medications, infections), and the importance of adherence to treatment and regular follow-up.

Tertiary

Tertiary prevention aims to minimize the impact of the disease and prevent complications once it is established. * Regular Monitoring: Close clinical follow-up, assessment of respiratory function, and monitoring for medication side effects. * Prevention of Myasthenic Crisis: Early recognition and aggressive management of triggers (e.g., prompt treatment of infections, cautious use of medications, avoidance of unnecessary stress). * Management of Comorbidities: Addressing osteoporosis from long-term steroid use (calcium, vitamin D, bisphosphonates), managing diabetes, hypertension, and other autoimmune conditions. * Vaccinations: Ensure patients on immunosuppressive therapy receive recommended vaccinations (e.g., annual influenza, pneumococcal, COVID-19) to prevent severe infections. Live attenuated vaccines are generally contraindicated in immunosuppressed patients. * Rehabilitation: Physical, occupational, and speech therapy to maintain function, improve quality of life, and cope with chronic symptoms.

Special Populations

Pediatric

• Juvenile Myasthenia Gravis (JMG): Onset before age 18.
  • Can be transient (neonatal MG), congenital (genetic defects at NMJ, non-autoimmune), or autoimmune.
  • Often has a good prognosis, with higher rates of spontaneous remission than adult MG.
  • Treatment: Pyridostigmine, corticosteroids, and steroid-sparing agents are used, similar to adults, but with careful attention to growth and developmental side effects.
  • Thymectomy: Considered for generalized AChR-positive JMG, similar to adults, but indications and timing can be more controversial in very young children.

Geriatric

• Late-Onset MG (LOMG): Onset after age 50.
  • More common in males.
  • Often presents with bulbar and respiratory weakness, and a higher proportion may have thymoma or thymic atrophy.
  • Treatment: Similar principles, but increased susceptibility to medication side effects (e.g., osteoporosis, infections, cardiovascular effects from steroids). Careful dose titration and monitoring are essential.
  • Comorbidities are more common and can complicate management.

Pregnancy

• Disease Course: MG usually improves or remains stable during pregnancy, but exacerbations can occur, particularly in the first trimester or postpartum period.
• Medication Safety:
  • Pyridostigmine: Generally safe throughout pregnancy.
  • Corticosteroids (Prednisone): Considered safe; typically continued or initiated as needed.
  • Azathioprine: Considered relatively safe and often continued throughout pregnancy if effective.
  • Mycophenolate Mofetil: Contraindicated in pregnancy due to teratogenicity. Patients should switch to other agents if planning pregnancy.
  • IVIG and PLEX: Safe for acute exacerbations during pregnancy.
• Delivery: Vaginal delivery is usually possible. Epidural anesthesia is preferred. Neuromuscular blockers should be used with caution during C-section due to increased sensitivity.
• Neonatal Myasthenia Gravis: Occurs in 10-20% of infants born to mothers with MG due to transplacental transfer of AChR antibodies. It is usually transient, presenting with generalized weakness, poor suck, respiratory distress. Management is supportive, and symptoms resolve within weeks to months as maternal antibodies clear.

Comorbidities

• Autoimmune Diseases: MG frequently coexists with other autoimmune conditions, especially thyroid diseases (Grave's disease, Hashimoto's thyroiditis), rheumatoid arthritis, and lupus. Management requires careful consideration of drug interactions and overlapping symptoms.
• Cardiac Disease: Rarely, antibodies against titin and ryanodine receptors (often with thymoma) can cause myocarditis or cardiomyopathy.
• Pulmonary Disease: Pre-existing lung conditions (e.g., COPD) increase the risk and severity of respiratory complications in MG.
• Drug Interactions: Clinicians must be vigilant for medications that can exacerbate MG or interact with immunosuppressants.

Clinical Pearls

Diagnostic

• Fluctuating Weakness is Key: The hallmark of MG is variability and fatigability of weakness. Always ask about diurnal variation and worsening with activity.
• Think MG for Ocular Symptoms: Unexplained fluctuating ptosis or diplopia should always prompt consideration of MG.
• Antibody Testing is First Line: AChR-Ab are highly specific. If negative, pursue MuSK-Ab, LRP4-Ab, and then electrophysiology.
• SFEMG is Most Sensitive: If clinical suspicion remains high despite negative antibody tests and RNS, SFEMG is the most sensitive test for NMJ dysfunction.
• Don't Forget the Thymus: A chest CT is mandatory for all new MG diagnoses to rule out thymoma.
• Ice Pack Test: A simple, quick, and highly specific bedside test for ptosis.

Treatment

• Pyridostigmine for Symptoms: It's a symptomatic treatment, not disease-modifying. Start low, go slow. Watch for cholinergic side effects.
• Corticosteroids are Foundational Immunosuppression: But use judiciously due to side effects. Consider steroid-sparing agents early to minimize long-term steroid burden.
• Thymectomy Can Be Curative: For selected patients with generalized AChR-positive MG, especially EOMG. It's not just for thymoma.
• Myasthenic Crisis is a Medical Emergency: Always assess respiratory function (FVC, NIF). Prompt intubation, IVIG/PLEX, and supportive care are life-saving. Withhold/reduce pyridostigmine during crisis.
• New Biologics Offer Hope: For refractory MG, consider agents like efgartigimod, eculizumab, ravulizumab, rituximab, and others, especially for specific antibody subtypes.

Pitfalls

• Misdiagnosis: MG can mimic other neurological conditions (e.g., stroke, brainstem lesions, motor neuron disease, mitochondrial disorders, botulism).
• Underestimation of Respiratory Risk: Patients with seemingly mild bulbar or limb weakness can rapidly develop respiratory compromise. Monitor FVC vigilantly.
• Overdosing Pyridostigmine: Can lead to cholinergic crisis, which can be difficult to differentiate from myasthenic crisis.
• Failure to Look for Thymoma: Missing a thymoma has significant prognostic and therapeutic implications.
• Use of Contraindicated Medications: Certain drugs can precipitate or worsen MG (e.g., aminoglycosides, fluoroquinolones, beta-blockers, magnesium). Always review current medications carefully.
• Not Vaccinating Immunocompromised Patients: Increased infection risk is a major concern with immunosuppression.
• Ignoring Patient Fatigue: Even in well-controlled patients, chronic fatigue significantly impacts quality of life and requires active management strategies.

Recent Updates

Guidelines

• International Consensus Guidance for Management of Myasthenia Gravis (ICGMG): Regularly updated guidelines provide comprehensive, evidence-based recommendations for diagnosis and management, published by a consensus of international experts (e.g., the 2020 update). These guidelines are a primary reference for clinicians.
• AAN (American Academy of Neurology) Guidelines: Periodically updated, addressing specific aspects like thymectomy or treatment for ocular MG.

Evidence

• Effectiveness of Thymectomy: The MGTX trial (Thymectomy for Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy) provided high-level evidence supporting thymectomy for non-thymomatous generalized AChR-positive MG patients aged <65 years, showing improved clinical outcomes and reduced need for immunosuppression.
• Novel Biologics:
  • FcRn Inhibitors (Efgartigimod, Rozanolixizumab): Demonstrate significant reductions in IgG autoantibodies and clinical improvement, offering a new class of targeted therapy for generalized MG (AChR-positive, and Rozanolixizumab also for MuSK-positive).
  • Complement Inhibitors (Eculizumab, Ravulizumab, Zilucoplan): Have shown sustained efficacy and safety in refractory AChR-positive generalized MG, providing targeted blockade of the complement cascade.
  • Ongoing research is exploring other targets and pathways, including anti-BCMA antibodies and gene therapies.

Controversies

• Optimal Timing and Indications for Thymectomy: While strong evidence exists for AChR-positive generalized MG, the role of thymectomy in seronegative MG, MuSK-MG, or very late-onset MG remains less clear.
• Long-Term Strategy for Immunosuppression: Debates continue regarding the optimal duration of corticosteroid use, the best steroid-sparing agent for individual patients, and when to consider withdrawal of immunosuppressants.
• Management of Seronegative MG: As more antibodies (LRP4, agrin, titin) are identified, the "seronegative" group shrinks, but management remains challenging for those without identified antibodies.
• Sequence of Biologic Therapies: With multiple new agents becoming available, determining the optimal sequence and combination of biologics for refractory MG is an evolving area.

Key References

Guidelines

• Narayan, R., et al. (2020). International consensus guidance for management of myasthenia gravis: 2020 update. Neurology, 95(16), 760-779. (A key reference for comprehensive management guidelines).
• Skeie, G. O., et al. (2018). Guidelines for the treatment of autoimmune neuromuscular transmission disorders – European Federation of Neurological Societies/Peripheral Nerve Society Task Force. European Journal of Neurology, 25(1), 1-17.

Studies

• Wolfe, G. I., et al. (2016). Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine, 375(6), 511-522. (The landmark MGTX trial).
• Howard, J. F., et al. (2017). Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody–positive refractory generalized myasthenia gravis (REGAIN): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Neurology, 16(12), 976-986. (Pivotal trial for eculizumab).
• Howard, J. F., et al. (2021). Efgartigimod in Generalized Myasthenia Gravis: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial. New England Journal of Medicine, 385(7), 593-605. (Pivotal trial for efgartigimod).

Reviews

• Gilhus, N. E., & Verschuuren, J. J. G. M. (2015). Myasthenia gravis: a disease with many faces. Journal of Internal Medicine, 278(4), 423-430.
• Murthy, J. M. K. (2023). Myasthenia gravis: Treatment advances and challenges. Annals of Indian Academy of Neurology, 26(1), 3. (Recent review on treatment advances).
• Finley, A. D., et al. (2023). Myasthenia Gravis in the Older Patient. Seminars in Neurology, 43(3), 329-340. (Focus on geriatric population).